Echosens Shares BlueCross BlueShield of Tennessee Medical Policy Update Clarifying Coverage for FibroScan® and Other Noninvasive Elastography Technologies
Echosens Shares BlueCross BlueShield of Tennessee Medical Policy Update Clarifying Coverage for FibroScan® and Other Noninvasive Elastography Technologies
PR Newswire
WESTBOROUGH, Mass., July 15, 2026
WESTBOROUGH, Mass., July 15, 2026 /PRNewswire/ -- Echosens today announced that BlueCross BlueShield of Tennessee (BCBSTN) has revised its medical policy governing noninvasive imaging for chronic liver disease, effective July 31, 2026.
Under the revised policy, BCBSTN continues to consider transient elastography imaging with FibroScan® medically necessary for the evaluation and monitoring of chronic liver disease. The policy also states that other noninvasive imaging technologies that map the elastic properties of soft tissue are considered investigational and notes that evidence is currently insufficient to support coverage for certain alternative transient elastography techniques, including ViTE (e.g.Hepatus® / Mindray) and MAP (e.g. Liverscan C / Eieling) technologies.
"The updated policy provides additional clarity for providers by distinguishing between noninvasive technologies that may appear similar but have different evidence bases and coverage determinations," said Amy Conner, MPH, Director of Market Access and Pharma at Echosens. "As new technologies enter the market, medical policies help clinicians identify which technologies have sufficient evidence to support coverage for specific clinical applications."
FibroScan® exams that include image guidance and provider interpretation for ultrasound elastography (USE) purposes are consistent with the requirements for CPT code 76981. If these requirements are not met, liver elastography should instead be billed using CPT code 91200. Additional coding and billing information is available here.
About Echosens
A pioneer in its field, Echosens significantly changed the practice of liver assessment with FibroScan®, the non-invasive solution for comprehensive management of liver health. FibroScan® is recognized worldwide and validated by more than 5,600 peer-reviewed publications, including nearly 220 international guidelines. https://www.echosens.com/
SOURCE Echosens
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for October
The 10 Best Companies to Invest in Now
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
3 Stocks to Invest In With More Room to Run
United States